search
Back to results

Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics

Primary Purpose

Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
Sponsored by
Medtronic Diabetes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 1 Diabetes Mellitus

Eligibility Criteria

2 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Individual is 2 - 80 years of age at time of enrollment
  2. A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  3. Adequate venous access as assessed by investigator or appropriate staff
  4. Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity ratio. Subjects without ratios may participate under observation only

Exclusion Criteria:

  1. Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by a qualified individual.
  2. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)
  3. Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
  4. Subject is female and has a positive pregnancy screening test
  5. Female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator
  6. Subject is female and plans to become pregnant during the course of the study
  7. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment
  8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment.
  10. Subject has a history of a seizure disorder
  11. Subject has central nervous system or cardiac disorder resulting in syncope
  12. Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  13. Subject has a hematocrit (Hct) lower than the normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents)
  14. Subject has a history of adrenal insufficiency
  15. Subject is a member of the research staff involved with the study.

Sites / Locations

  • AMCR Institue
  • Sansum Diabetes Research Institute
  • SoCal Diabetes
  • Diablo Clinical Research
  • Diablo Clinical Research
  • Barbara Davis Center - Adults
  • Barbara Davis Center for Childhood Diabetes (Pediatric)
  • University of South Florida
  • Rocky Mountain Diabetes and Osteoporosis Center
  • IDERC
  • Mayo Clinic (Rochester MN)
  • AM Diabetes & Endocrinology Center
  • Texas Diabetes and Endocrinology
  • University of Virgina
  • Rainer Clinical Research Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Subjects with diabetes wearing Guardian™ Sensor (3)

Arm Description

Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.

Outcomes

Primary Outcome Measures

Percentage of Readings Within 20% Agreement
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values < 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.

Secondary Outcome Measures

Full Information

First Posted
May 23, 2019
Last Updated
May 11, 2021
Sponsor
Medtronic Diabetes
search

1. Study Identification

Unique Protocol Identification Number
NCT03966911
Brief Title
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Official Title
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
June 14, 2019 (Actual)
Primary Completion Date
May 13, 2020 (Actual)
Study Completion Date
May 13, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Diabetes

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
Detailed Description
The study is a multi-center, prospective, single-sample correlational design without controls. The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
335 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects with diabetes wearing Guardian™ Sensor (3)
Arm Type
Other
Arm Description
Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
Intervention Type
Device
Intervention Name(s)
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
Intervention Description
Continuous Glucose Monitoring and frequent sample testing
Primary Outcome Measure Information:
Title
Percentage of Readings Within 20% Agreement
Description
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values < 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.
Time Frame
7 days (170 hours)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individual is 2 - 80 years of age at time of enrollment A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis Adequate venous access as assessed by investigator or appropriate staff Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity ratio. Subjects without ratios may participate under observation only Exclusion Criteria: Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by a qualified individual. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection) Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks Subject is female and has a positive pregnancy screening test Female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator Subject is female and plans to become pregnant during the course of the study Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment. Subject has a history of a seizure disorder Subject has central nervous system or cardiac disorder resulting in syncope Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease Subject has a hematocrit (Hct) lower than the normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents) Subject has a history of adrenal insufficiency Subject is a member of the research staff involved with the study.
Facility Information:
Facility Name
AMCR Institue
City
Escondido
State/Province
California
ZIP/Postal Code
92026
Country
United States
Facility Name
Sansum Diabetes Research Institute
City
Santa Barbara
State/Province
California
ZIP/Postal Code
93105
Country
United States
Facility Name
SoCal Diabetes
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Facility Name
Diablo Clinical Research
City
Walnut Creek
State/Province
California
ZIP/Postal Code
92025
Country
United States
Facility Name
Diablo Clinical Research
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Barbara Davis Center - Adults
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Barbara Davis Center for Childhood Diabetes (Pediatric)
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Rocky Mountain Diabetes and Osteoporosis Center
City
Idaho Falls
State/Province
Idaho
ZIP/Postal Code
83404
Country
United States
Facility Name
IDERC
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50265
Country
United States
Facility Name
Mayo Clinic (Rochester MN)
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
AM Diabetes & Endocrinology Center
City
Bartlett
State/Province
Tennessee
ZIP/Postal Code
38133
Country
United States
Facility Name
Texas Diabetes and Endocrinology
City
Austin
State/Province
Texas
ZIP/Postal Code
78749
Country
United States
Facility Name
University of Virgina
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Facility Name
Rainer Clinical Research Center
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics

We'll reach out to this number within 24 hrs